A theoretical pharmacokinetic/pharmacodynamic model in which the degree of inflammation (reflected by the poor surrogate marker Crohn’s Disease Activity Index), changed by the binding of IFX to TNF in patients with CD was previously proposed [29]. The gene discussed is TNF; the disease is Crohn disease.